Fresenius Medical Care AG & Co. KGaA (FMS) stock is soaring 7.81% in Tuesday's trading session following the release of its impressive first-quarter 2025 results. The German dialysis company reported better-than-expected earnings and revenue, demonstrating strong organic growth and improved profitability.
The company's Q1 2025 highlights include: - Organic revenue growth of 5%, driven by both Care Enablement and Care Delivery segments - Operating income grew 11% at constant currency, resulting in margin expansion - Reported net income increased by 113% - FME25 transformation program delivered EUR 68 million in additional sustainable savings
Investors were particularly encouraged by Fresenius Medical Care's confirmed full-year 2025 outlook, which projects positive revenue growth and a high-teens to high-twenties percent increase in operating income excluding special items. The company's ability to maintain stable U.S. same-market treatment growth despite a severe flu season also contributed to the positive market reaction. Analysts from Morgan Stanley and Deutsche Bank have noted the solid results, although some caution remains regarding U.S. dialysis treatment growth and potential foreign-currency exchange pressures on earnings estimates.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。